2d. ICON plc ICLR is well-poised to grow in the upcoming quarters, driven by its strategic additions. Leveraging AI and technology advancements, ...

It has been about a month since the last earnings report for Icon PLC (ICLR). Shares have lost about 9.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

The contract research organization posted revenue of $2.02 billion in the period, which also beat Street forecasts. Six analysts surveyed by Zacks expected $1.99 billion. Icon PLC expects full-year ...

A month has gone by since the last earnings report for Icon PLC (ICLR). Shares have lost about 8.9% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading ...

Icon PLC (ICLR) came out with quarterly earnings of $3.19 per share, beating the Zacks Consensus Estimate of $3.08 per share. This compares to earnings of $3.47 per share a year ago. These figures ...

Icon Plc (NASDAQ:ICLR) is a contract research organization (“CRO”). In the Q3 2024 letter, I highlighted our investment in Medpace another CRO that directly competes with Icon.

More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, F-4, S-8, F-3 and certain ...

Investors might want to bet on Icon PLC (ICLR), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...

ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced the expansion of its portfolio of artificial intelligence (AI) tools ...

A month has gone by since the last earnings report for Icon PLC (ICLR). Shares have lost about 8.9% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading ...

ICON plc is a world-leading healthcare intelligence and clinical research organization. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, ...